Use of perfluorocarbon compound in the endorectal coil to improve MR spectroscopy of the prostate

American Journal of Roentgenology

Volumn 190, Issue 4, 2008, Pages 1055-1059

  Choi, Haesun ^a   Ma, Jingfei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinoma; MR spectroscopy; Perfluorocarbon; Prostate

Indexed keywords

CHOLINE; FLUOROCARBON; POLYAMINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; IMAGE ENHANCEMENT; IMAGE QUALITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; SCORING SYSTEM; ADENOCARCINOMA; AIR; CANCER STAGING; COMPARATIVE STUDY; INSTRUMENTATION; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AIR; FLUOROCARBONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 42449126970     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2998     Document Type: Article

References (18)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007. http://www.cancer.org/downloads/STT/ CAFF2007PWSecured.pdf. Accessed January 8, 2008
2. Jacobson JO, Brodsky G, DuBeau C, et al. Cancer of the prostate. In: Osteen RT, ed. Cancer manual. Boston, MA: American Cancer Society, 1996:446-461
3. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997; 24:299-306
4. Whelan P. Multidisciplinary symposium: prostate cancer - planning primary therapy. Cancer Imaging 2000; 1:44-51
5. Casciani E, Polettini E, Bertini L, et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 2007; Feb 10 [Epub ahead of print]
6. Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007; 42:116-122
7. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging: clinicopathologic study. Radiology 1999; 213:473-480
8. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404
9. Eilenberg SS, Tartar VM, Mattrey RF. Reducing magnetic susceptibility differences using liquid fluorocarbon pads (Sat Pad): results with spectral presaturation of fat. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:1477-1483
10. Brown JJ. Gastrointestinal contrast agents for MR imaging. Magn Reson Imaging Clin N Am 1996; 4:25-35
11. Mattrey RF. The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif Cells Blood Substit Immobil Biotechnol 1994; 22:295-313
12. F2 Chemicals Limited. For selective direct fluorination and Flutec perfluorocarbon fluids: medical applications. http://www.fluoros.co.uk/data/ medical_applications.php. Accessed January 8, 2008
13. Choi H, Zhou X, Ma J. Use of perfluorocarbon (PFC) in magnetic resonance spectroscopy (MRS) of prostate: a method to improve the line-width and quality of spectra (abstr SSA07-02). RSNA 2004. Oak Brook, IL: Radiological Society of North America, 2004. http://archive.rsna.org/index.cfm?em_id=4407696&event= 1. Accessed January 8, 2008
14. Guclu CC, Figueiredo E, Prando A, Racy D, Becerra R. A method to improve the spectral resolution in prostate spectroscopy (abstract). In: 2004 Scientific Meeting proceedings. Berkeley, CA: International Society for Magnetic Resonance in Medicine, 2004:11
15. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostate biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236:903-910
16. Romijn JC. Molecular and cellular biology of prostate cancer. In: Karr JP, Coffey DS, Smith RG, Tindall DJ, eds. Polyamine requirement of prostate cancer cell proliferation. New York, NY: Plenum, 1991:103-114
17. Schipper RG, Romijn JC, Cuijpers VM, Verhofstad AA. Polyamines and prostatic cancer. Biochem Soc Trans 2003; 31:375-380
18. Food and Drug Administration. Information sheet guidance for IRBs, clinical investigators, and sponsors: significant risk and nonsignificant risk medical device studies. Rockville, MD: Food and Drug Administration, 2006. http://www.fda.gov/oc/ohrt/irbs/devrisk.pdf. Accessed January 8, 2008